CORT: Corcept Therapeutics Company Short-Term Debt

Symbol and logo of brand Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT) is integrating ESG principles into the synthesis of metabolic agents while adhering to research ethics. The company's short-term debts reflect liability dynamics, where the indicator value stands at 0.00. Geopolitical tensions are hindering international trials and reducing licensing payments. Simultaneously, Corcept Therapeutics is implementing robotic receptor screening to automate the search for new drug formulas.

CORT (Corcept Therapeutics Inc.) Company Short-Term Debts history from 07/04/2022 to 10/30/2026

CORT (Corcept Therapeutics Corp): analytical breakdowns and indicator data

- current quotes and average value forecast:
Price Chart Corcept Therapeutics Incorporated|CORT - Fair Value Consensus
- market capitalization information:
Market Value Corcept Therapeutics Incorporated|CORT - Real Price to Acquire Entire Company
- shareholders' equity book value data:
Book Value per Share Corcept Therapeutics|CORT - Book Capitalization|Market Cap to Net Assets Ratio corcept.com|CORT - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity Corcept Therapeutics|CORT - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Corcept Therapeutics|CORT - Company Cumulative Debt|Debt to Book Value Corcept Therapeutics Incorporated|CORT - Amount of Long-Term Liabilities|Company Short-Term Debts Corcept Therapeutics|Quick Ratio corcept.com
- net income and valuation multiples indicators:
CORT - Company Net Income
Basic company analysis:Corcept Therapeutics Incorporated - CORT
Mass-produced product of Corcept Therapeutics Corp

Corcept Therapeutics revenue relies on the exclusive sale of Korlym, making liquidity stability critical for maintaining the innovation cycle. This metric aggregates all obligations maturing within one year, allowing for an assessment of cash gap risks and the actual speed of debt service between quarterly reports through the monitoring of short-term liabilities.

Who Corcept Therapeutics competes with

ASND - Company Short-Term Debt|Company Short-Term Loans and Borrowings MDGL (Madrigal Pharmaceuticals Inc)|Rhythm Pharmaceuticals Inc (RYTM) - Company Short-Term Debt|Company Current Liabilities Akero Corp|MTSR (Metsera Inc) - Company Short-Term Debts|Company Short-Term Debts moonlaketx.com|Company Current Liabilities CRNX (Crinetics)|NAMS (NewAmsterdam Pharma Company) - Company Short-Term Loans and Borrowings|Company Short-Term Debt Soleno SLNO|FOLD - Company Current Liabilities|89bio, Inc. - Company Short-Term Debts|Short-Term Debt agios.com|GPCR (Structure Therapeutics Inc.) - Company Current Liabilities|MDXG: Amount of Current Liabilities|RZLT (Rezolute Corp) - Company Short-Term Debts|Company Short-Term Debts Lexicon Corp|Company Short-Term Debts MBX|Company Short-Term Debt ALT (altimmune.com)|Company Short-Term Debt Aardvark Therapeutics AARD|Sagimet Biosciences, Inc. (SGMT) - Short-Term Debt|BIOA - Company Short-Term Debt|BMEA: Company Short-Term Debt|QNCX: Company Short-Term Debts|GUTS - Short-Term Debt Volume|Company Short-Term Debt vTv Therapeutics, Inc.|Agape ATP Corp. (ATPC) - Short-Term Debt Volume|Company Short-Term Debt Pluri Inc. (PLUR)|Company Current Liabilities synlogictx.com SYBX|Company Short-Term Debts LPCN (Lipocine Inc.)|MTNB - Company Current Liabilities|SPRB - Company Short-Term Debt|Short-Term Debt Galecto Inc|Carmell Corp (CTCX) - Company Short-Term Debt|Lumos Therapeutics - Company Short-Term Loans and Borrowings|ONVO (Organovo Holdings, Inc.) - Company Short-Term Debts|Company Current Liabilities radiuspharm.com (RDUS)